SCHEMBL263291

SCHEMBL263291

Nc1nc(NC(=O)c2conc2C(F)(F)F)ccc1-c1ccccc1OC(F)(F)F

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 8/20 0.79
SCN9A Q15858 5/20 0.79
SCN5A Q14524 1/20 0.79
SCN2A Q99250 1/20 0.79
SCN3A Q9NY46 1/20 0.79
S1PR1 P21453 2/20 0.37
S1PR3 Q99500 2/20 0.37
KIT P10721 1/20 0.36
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
DHODH Q02127 1/20 0.36
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
CYP2C9 P11712 1/20 0.35
UGCG Q16739 1/20 0.35
KCNK3 O14649 1/20 0.34
KCNK9 Q9NPC2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263240 0.90 SCN10A (0.65) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL262780 0.89 SCN10A (1.00) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL3095874 0.86 SCN10A (0.60) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL263458 0.85 SCN10A (0.58) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL14237407 0.80 SCN10A (1.00) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL263869 0.80 SCN10A (0.52) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL263563 0.79 SCN10A (0.70) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL14237357 0.79 SCN10A (0.58) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL264140 0.79 SCN10A (0.78) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL263316 0.79 SCN10A (0.81) SCN10ASCN9ASCN5ASCN2ASCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP claimed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US claimed
JP-4657384-B2 2011-03-23 JP claimed
JP-2010526050-A 2010-07-29 JP claimed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP claimed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US claimed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO claimed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 SCN10A 358/4885SCN9A 491/4885SCN5A 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.